Clinical trials
HER2-negative Breast Cancer clinical trials
Below are recruiting her2-negative breast cancer clinical trials, each written for real people, not researchers. We’re tracking 265 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07237256RecruitingPhase 3
Testing less chemo for HR+ HER2- breast cancer with ribociclib
This trial tests whether some people with hormone receptor-positive, HER2-negative early breast cancer can safely receive less chemotherapy when also taking the targeted drug ribociclib after surgery. You may qualify if you have a specific stage of breast cancer and are planning to take hormone therapy for at least 5 years.
AmiensAges 18 years+ - NCT07233928Recruiting
Breast cancer protein study in different subtypes
This trial takes a close look at the proteins inside breast cancer cells, using samples from people with different subtypes. It aims to better understand how each type behaves, which could help guide future treatments.
ToulouseAges 18 years+ - NCT07222215RecruitingPhase 2
Capacitabine with or without elacestrant for ER+ breast cancer
This trial tests if adding a new oral targeted therapy (elacestrant) to standard chemotherapy (capecitabine) works better than chemotherapy alone for people with a specific type of advanced breast cancer that is hormone-sensitive (ER-positive) and has stopped responding to hormone therapy.
Boston, MassachusettsAges 18 years+ - NCT07227831Recruiting
TheraBionic device for advanced hormone-positive breast cancer
This trial tests a device called TheraBionic P1, which uses low-level radiofrequency energy to treat advanced breast cancer that has stopped responding to standard treatments. It may offer a new option for people who have exhausted other therapies.
Bay City, MichiganAges 22 years+ - NCT07218432Recruiting
TheraBionic device study for hormone-positive breast cancer
This trial tests a device called TheraBionic P1, which uses low-level radiofrequency energy, for women with early-stage hormone receptor-positive, HER2-negative breast cancer. It is given before surgery to see if it can help shrink the tumor.
Clarkston, MichiganAges 22 years+ - NCT07207070RecruitingPhase 3
New drug combination for PIK3CA-mutated breast cancer
This trial tests a new combination of two drugs (JS105 plus dalpiciclib and fulvestrant) against a standard combination (dalpiciclib plus fulvestrant) for people whose breast cancer has a PIK3CA mutation. The goal is to see if adding JS105 helps control the cancer longer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07198724RecruitingPhase 1/Phase 2
A study of elacestrant plus Enhertu for advanced breast cancer
This trial tests a new combination of two targeted drugs (elacestrant and Enhertu) for people with a specific type of advanced breast cancer (HR-positive, HER2-low or ultra-low) that did not respond to standard treatments like CDK4/6 inhibitors. The goal is to see if this combination works better than current options.
Boston, MassachusettsAges 18 years+ - NCT05535413RecruitingPhase 1/Phase 2
UTD1 plus capecitabine for HER2-negative breast cancer brain mets
This trial tests whether adding a study drug called UTD1 to capecitabine can shrink or control breast cancer that has spread to the brain. It’s for people with HER2-negative metastatic breast cancer who have brain metastases and meet specific safety and lab requirements.
ChangshaAges 18–70 - NCT07193394RecruitingPhase 2
Tucatinib and trastuzumab for HER3-mutant breast cancer
This trial tests a combination of two targeted drugs (tucatinib and trastuzumab) for people with a specific gene change (HER3 mutation) in advanced breast cancer that has spread or cannot be removed by surgery. It may be an option if you have already had at least two previous treatments.
BordeauxAges 18 years+ - NCT07190443RecruitingPhase 3
Abemaciclib after local recurrence in HR+ HER2- breast cancer
This trial tests whether adding a targeted drug (abemaciclib) to standard treatment helps prevent breast cancer from coming back again after a local recurrence in women with HR-positive, HER2-negative breast cancer.
Koto-ku, TokyoAges 18 years+ - NCT06225284RecruitingPhase 2
Chemotherapy with or without hormone drug for premenopausal TNBC
This trial tests whether adding a hormone-blocking drug (GnRH agonist) to standard chemotherapy before surgery helps premenopausal women with triple-negative breast cancer. It aims to improve treatment outcomes by targeting hormones that may fuel tumor growth.
TaipeiAges 18 years+ - NCT06950086RecruitingPhase 1/Phase 2
TYK-00540 tablets for advanced solid tumors
This trial tests a new tablet, TYK-00540, alone or with another drug, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07180160RecruitingPhase 2
A study of QL1706 for HR-positive, HER2-negative breast cancer
This trial tests a new drug combination (iparomlimab and tuvonralimab, also called QL1706) for people with advanced breast cancer that is hormone receptor-positive and HER2-negative. It may be an option if standard treatments have stopped working.
ShanghaiAges 18 years+ - NCT07164976RecruitingPhase 1/Phase 2
Ribociclib for advanced HR+ HER2- breast cancer
This trial tests a new combination of ribociclib and anastrozole as a first treatment for advanced hormone receptor-positive, HER2-negative breast cancer that has not been treated before. It may help if you have not received any prior therapy for metastatic disease.
NagoyaAges 18 years+ - NCT07162675Recruiting
Step count and treatment response in breast cancer patients
This study looks at how your daily step count, measured by a smartwatch, relates to how well your breast cancer responds to treatment before surgery. It may help show if being more active during chemotherapy leads to better outcomes.
Ankara, YenimahalleAges 18 years+ - NCT07112053RecruitingPhase 2
Vaccine with hormone therapy or chemo for advanced breast cancer
This trial tests a vaccine (STEMVAC) given with your standard hormone therapy or chemotherapy. It is for people with advanced hormone receptor-positive, HER2-negative breast cancer who are already on certain treatments. The goal is to see if adding the vaccine can help control the cancer better.
Seattle, WashingtonAges 18 years+ - NCT07106632RecruitingPhase 3
Genomic test to guide chemotherapy in young women with breast cancer
This trial uses a genomic test called Prosigna to help decide whether young women with hormone-sensitive breast cancer need chemotherapy after surgery. It aims to avoid unnecessary chemotherapy in those who can safely skip it.
BrusselsAges 35–45 - NCT04947189RecruitingPhase 1/Phase 2
Seviteronel plus chemo for advanced triple-negative breast cancer
This trial tests seviteronel together with standard chemotherapy to treat certain types of advanced breast cancer that has spread. It’s looking to see how well the combination works and how safe it is, especially for cancers that are androgen-receptor positive.
Darlinghurst, New South WalesAges 18 years+ - NCT05362760RecruitingPhase 4
Abemaciclib plus hormone therapy, with digital side-effect tracking
This trial tests whether adding abemaciclib to standard hormone (endocrine) therapy can improve outcomes for certain types of advanced breast cancer. It also uses a phone app to help you and the team track side effects so problems can be caught early.
AalenAges 18 years+ - NCT07078604RecruitingPhase 2
Vaccine with chemotherapy for advanced triple-negative breast cancer
This trial tests a cancer vaccine called STEMVAC combined with chemotherapy in people with a type of breast cancer that has spread and does not have certain markers. The goal is to see if adding the vaccine helps the chemotherapy work better.
Seattle, WashingtonAges 18 years+ - NCT05333328RecruitingPhase 4
Test of ovarian function suppression for low-risk premenopausal node+ breast cancer
This trial studies whether ovarian function suppression (a treatment that lowers hormone production from the ovaries) helps women with hormone-receptor positive, HER2-negative breast cancer that has spread to lymph nodes, but who have a low-risk result on a genomic test. It may help reduce breast cancer recurrence while avoiding more intensive treatment for those who are lower risk.
Seoul, KoreaAges 20–50 - NCT07071038RecruitingPhase 2
Switching medication to relieve side effects from aromatase inhibitors
This trial tests whether switching to a different aromatase inhibitor or using standard treatments works better for managing side effects in breast cancer survivors. It aims to help you stay on hormone therapy longer with fewer discomforts.
Lebanon, New HampshireAges 18 years+ - NCT07062965RecruitingPhase 3
PF-07248144 with fulvestrant for HR+ HER2- advanced breast cancer
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
Chandler, ArizonaAges 18 years+ - NCT07054190RecruitingPhase 2
Testing inavolisib for early-stage PIK3CA-mutated breast cancer
This study tests a new drug called inavolisib for people with early-stage breast cancer that has a specific genetic change (PIK3CA mutation). The goal is to see if adding this drug to standard hormone therapy is safe and effective before surgery.
Los Angeles, CaliforniaAges 18 years+
Hear when a new HER2-negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her2-negative breast cancer?
- Yes. Clin2 currently lists 265 recruiting her2-negative breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her2-negative breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her2-negative breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- HR-positive, HER2-negative Advanced Breast Cancer
- Hormone Receptor Positive / HER2-negative Breast Cancer
- Metastatic Breast Cancer ( HER2 Negative)
- Triple Negative Breast Cancer
- HER2-positive Breast Cancer
- HR+/HER2- Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.